The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•20 April 2026•

1 min read

IGC Pharma Secures Authorization for Psilocybin Research in Colombia

Key Facts

1IGC Pharma received authorization in Colombia to synthesize, formulate, and conduct development activities involving psilocybin at its Bogotá facility.

2The authorization was granted under the oversight of the Fondo Nacional de Estupefacientes (FNE).

3The company plans to use psilocybin to explore treatments for neuropsychiatric symptoms associated with dementia.

IGC Pharma has officially received regulatory authorization in Colombia to synthesize, formulate, and conduct research activities involving psilocybin at its Bogotá facility. The authorization was granted under the strict oversight of the Fondo Nacional de Estupefacientes (FNE), marking a significant regulatory milestone for the company. IGC Pharma intends to leverage psilocybin to explore novel treatments for neuropsychiatric symptoms associated with dementia. This move positions the company to capitalize on the growing scientific and investor interest in psychedelic-based therapeutics. By expanding its R&D capabilities, the company is diversifying its portfolio beyond its ongoing Alzheimer's clinical trials. The development reflects a broader trend of deregulation in the psychedelic pharmaceutical sector, potentially opening new avenues for growth.